RAS in FGF23: Another Piece in the Puzzle

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2014 Jan 4

PMID 24384015

Citations 1

Authors

Diana Ovejero

Michael T Collins

Affiliations

Soon will be listed here.

Citing Articles

Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia.

Liu S, Zhou X, Liu Y, Zhang J, Xia W J Bone Oncol. 2024; 45:100600.

PMID: 38577550 PMC: 10990903. DOI: 10.1016/j.jbo.2024.100600.

References

Bhattacharyya N, Wiench M, Dumitrescu C, Connolly B, Bugge T, Patel H . Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012; 27(5):1132-41. PMC: 7448291. DOI: 10.1002/jbmr.1546. View

Eicher E, SOUTHARD J, Scriver C, Glorieux F . Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A. 1976; 73(12):4667-71. PMC: 431589. DOI: 10.1073/pnas.73.12.4667. View

Topaz O, Shurman D, Bergman R, Indelman M, Ratajczak P, Mizrachi M . Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004; 36(6):579-81. DOI: 10.1038/ng1358. View

PRADER A, Illig R, UEHLINGER E, Stalder G . [Rickets following bone tumor]. Helv Paediatr Acta. 1959; 14:554-65. View

Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M . Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012; 44(7):783-7. DOI: 10.1038/ng.2316. View

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt K . Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10):6120-3. PMC: 2637204. DOI: 10.1074/jbc.C500457200. View

Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T . FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004; 314(2):409-14. DOI: 10.1016/j.bbrc.2003.12.102. View

Meyer Jr R, Meyer M, Gray R . Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res. 1989; 4(4):493-500. DOI: 10.1002/jbmr.5650040407. View

Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y . Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348(17):1656-63. DOI: 10.1056/NEJMoa020881. View

10.

Isakova T, Wahl P, Vargas G, Gutierrez O, Scialla J, Xie H . Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12):1370-8. PMC: 3134393. DOI: 10.1038/ki.2011.47. View

11.

Imel E, Peacock M, Gray A, Padgett L, Hui S, Econs M . Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011; 96(11):3541-9. PMC: 3205884. DOI: 10.1210/jc.2011-1239. View

12.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View

13.

Bhattacharyya N, Chong W, Gafni R, Collins M . Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012; 23(12):610-8. PMC: 3502714. DOI: 10.1016/j.tem.2012.07.002. View

14.

Lim Y, Ovejero D, Sugarman J, DeKlotz C, Maruri A, Eichenfield L . Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2013; 23(2):397-407. PMC: 3869357. DOI: 10.1093/hmg/ddt429. View

15.

Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M . Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108(46):E1146-55. PMC: 3219119. DOI: 10.1073/pnas.1110905108. View

16.

Avitan-Hersh E, Tatur S, Indelman M, Gepstein V, Shreter R, Hershkovitz D . Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23. J Clin Endocrinol Metab. 2013; 99(1):E132-6. DOI: 10.1210/jc.2013-2813. View

17.

Riminucci M, Collins M, Fedarko N, Cherman N, Corsi A, White K . FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112(5):683-92. PMC: 182207. DOI: 10.1172/JCI18399. View

18.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View

19.

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

20.

Nesbitt T, Coffman T, Griffiths R, Drezner M . Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest. 1992; 89(5):1453-9. PMC: 443015. DOI: 10.1172/JCI115735. View